Erasca’s Pancreatic Cancer Drug Just Posted Strong Data. The Stock Market Reacted the Opposite Way.

Only investors in biotech seem to comprehend a certain kind of cruelty. After years of witnessing a company spend money on a truly challenging project, such as a medication that could potentially treat one of the most deadly cancers known to science, the data turns out to be more robust than anticipated, and the stock still plummets. That’s essentially what happened to Erasca in late April, and even by Wall Street’s notoriously callous standards, it was startling to watch.

The main medication from Erasca, ERAS-0015, is a pan-RAS molecular glue that targets RAS-driven cancers, such as pancreatic cancer, which still kills the vast majority of those who are diagnosed with it. By most clinical measures, the preliminary Phase 1 data, which was made public in late April, demonstrated response rates in patients with pancreatic and lung cancer that were higher than anticipated. Oncology-trained scientists referred to it as a “home run profile.” Executives at the company appeared genuinely motivated. Nevertheless, shares fell more than 53% in the hours following the announcement.

Naturally, the death was a part of what transpired. About a month after starting treatment, a 66-year-old man in the trial developed severe pneumonitis, or lung inflammation, and passed away after stopping aggressive care. Events of that nature are not and should not be disregarded. A drug’s entire future can be determined by safety signals in early-phase oncology trials, and investors have witnessed far too many promising candidates fail at this exact point. The pneumonitis may be a controllable class-related risk. It might not be, too. It is unsettling to have that uncertainty next to otherwise positive efficacy figures.

The legal threat then materialized. Erasca’s main competitor in the RAS-inhibitor market, Revolution Medicines, filed a patent challenge at what could be considered the worst possible time. Revolution had previously released Phase 3 results for its medication daraxonrasib, which showed that patients with pancreatic cancer had a median overall survival of 13.2 months compared to 6.7 months for chemotherapy—numbers that are truly remarkable in this illness. While its rival is already outperforming it in clinical development, Erasca, which is still in Phase 1, is pleading with investors to believe in a longer, more difficult road. Even in the best of situations, that is a difficult sell.

The market doesn’t seem to be penalizing Erasca for poor data. It’s penalizing the business for being in the shadow of a more advanced, better-resourced rival at a time when a single safety incident revealed all the underlying issues regarding differentiation. The same division can be seen in analyst opinions. Following the readout, Stifel called the data encouraging and increased its price target to $30. Despite raising its target from $2 to $9, BofA kept its Underperform rating due to doubts about how well Chinese trial data translates to American patient populations. The difference between $9 and $30 is not a numerical dispute. There is a dispute over the whole narrative.

As of 2026, Erasca had about $434 million in cash on hand, which is substantial for a clinical-stage business but much less than Revolution Medicines’ yearly expenditures across its growing portfolio. The question surrounding Thursday’s first-quarter earnings report is more about management’s ability to present a convincing future plan than it is about the loss per share, which analysts already predict will widen slightly to $0.105. In combination regimens, what does the tolerability advantage of ERAS-0015 really mean? Without dilutive financing rounds that penalize current shareholders, how does the company intend to grow?

It’s difficult to ignore the fact that Erasca’s predicament resembles a well-known biotech issue: the second-mover problem wrapped in technical jargon. The medication may actually be beneficial. Perhaps the science is correct. However, “might” is doing a lot of work in a race where Revolution Medicines already has Phase 3 survival data and a lead in regulatory talks. The safety data and combination trial outcomes in the coming months will be crucial. However, for the time being, the market has spoken loudly and in a way that no one in San Diego had anticipated.